Back to results
US 7,405,043 B2Granted
Responsiveness to therapy for liver disorders
AssigneeVita Genomics, Inc.
InventorsYuchi Hwang, Kuang-Den Chen, Chingwei Chang, Jui-Lin Chen, Ding-Shinn Chen, Pei-Jer Chen, Ming-Yang Lai
Life of this patent
Estimating the term…
Abstract
Sets of nucleic acids and methods for predicting a subject's responsiveness to therapy for liver disorders.
Claims4
A method of evaluating responsiveness of a subject to a drug, comprising
- providing a nucleic acid sample from a subject;
- determining a single nucleotide polymorphism genotype of a gene group that includes the human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK3CG, TAP2, and TGFBRAP1 genes;
- and
- comparing the single nucleotide polymorphism genotype of the human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK3CG, TAP2, and TGFBRAP1 genes with a predetermined single nucleotide polymorphism genotype for each of human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK1CG, TAP2, and TGFBRAP1 genes,
- whereby the subject is predicted to be responsive or non-responsive to the drug if the single nucleotide polymorphism genotype is identical to a predetermined single nucleotide polymorphism genotype of the human ADAR, CASP5, FGF1, ICSBP1, IFI44, PIK3CG, TAP2, and TGFBRAP1 genes.
2 more elements
Dependencies are inferred from the claim text.